Member Info for Moneymunch

Lol....how desperate are you mate.....you can bet short or you can bet long with Spreadex, and it's very for unusual for Spreadex to declare their customers long postitions in a stock....they know which way the sp will be heading....also worth noting is that Spreadex's share disclosure is a tiny fraction of the share transfers that have been documented over the last few months....someone is accumulating a very significant percentage of the company via EVG's broker Finncap...all will be revealed soon enough .....a new CEO and the very strong chance of a strategic investor/ JV partner...Gla holders.....a big week ahead and extremely exciting period for those invested....On and UP ;-)

Lol...is that the best you can do, you call me desperate , yet your deramping is juvenile, how old are you??? I'ts hilarious for you to state that Evgen will run out of money next September, not this September but September 2021...ha ha ha ha.....YOU ARE PATHETIC MATE!!! ho ho ho ;-)

Gla holders...a big week approaching imho, with the prospect of a new CEO in place for the start of September, and no doubt the catalyst of a flow positive news thereafter...On and UP!!! :-)

ADMIN !!! HOW MANY USERNAMES HAS THIS DESPERATE SAD CLOWN GOT REREGISTERED ????

Finncap 15/6/20...pre phase 2/3 Covid-19 patient trials

Forecasts and valuation.

We have increased operating expenses in FY 2021 to
reflect the delayed phasing of pre-clinical costs and completion of CMC package.

We introduce FY 2022 forecasts, with the cash runway extending into Q3 CY 2021.

We maintain our target price of 25p, which is based on an rNPV for SFX-01 in mBC only. This excludes any value attributable to other indications, such as in autism or NASH,which will be pursued through non-dilutive financing sources, or the potential value of SFX-01 as a sulforaphane delivery platform.

https://researchlibrary.finncap.com/File/View?file=c0021c92-9b4c-4987-82d5-825e28dc7824

....SFX-01 's Covid-19 patient trials are Phase 11/111 and are therefore much more advanced for approval and commercialisation compared with the other treatments in evaluation for Covid-19, with SNG for instance only just completing Phase 11 and so a long way to go before they're ready for Phase 11/111 ........Evgen has plenty of other near term news expected which could add significant value....watch this space...Gla holders.....Good news Imminent!!! ;-)

16/7/20

Next steps and summary

Focus on the strong efficacy data in breast cancer by planning and executing a Phase IIb trial

Phase II/III trial in ARDS patients commencing shortly - COVID-19

Reduce risk and increase probability of success by expanding breadth of clinical programmes:

Grant-funded, investigator-led clinical trials (no/smallcost to Evgen)

In indications with a strong mechanistic rationale (four collaborations announced todate in non-cancer indications)

Seek commercial partnerships based on Phase II results

Continue to explore other opportunities to monetise our IP assets

CEO recruitment process well-advanced

http://evgen.com/wp-content/uploads/2020/07/EVG-AGM-presentation-2020-16Jul20.pdf

SULSA

@SULSAtweets
Today meet Prof Albena Dinkova-Kostova

@UoDMedicine

, collaborating with

@ProfJDChalmers

to study whether the anti-inflammatory Nrf2 activator sulforaphane can improve recovery and decrease the need for mechanical ventilation in patients with severe COVID-19 #ScotlandRespondsC19

SULSA

@SULSAtweets

·

Aug 20

Today say hello to Dr Annya Bruce

@EdinburghUni

who is part of DEFINE COVID-19, a clinical trial now recruiting, comparing treatments against standard care to identify biomarkers that could help tailor therapies for future patients #ScotlandRespondsC19

https://twitter.com/profjdchalmers?lang=en

ps Prof Chalmers and Prof Albena Dinkova-Kostova are the lead investigators for SFX-01's proposed Covid-19 patient trials.

https://discovery.dundee.ac.uk/en/persons/albena-dinkova-kostova

Lol....FFS....once a troll always a troll........ha ha ha ha ha ha....who's going to be very upset when psoitive news flow arrives, what's you motive mate...what's your agenda you sad pathetic creature........ho ho ho .....a new CEO, a potential JV partnership, an update on their pipeline and academic collaborations, and Prof Chalmers ( lead investigator at Dunddee University ) tweet yesterday, suggests that SFX-01's Covid-19 Phase 2/3 patient trials will be coming soon......and all for a modest market cap of £18m...SNG's market cap is over £350m on successful phase 2 trials.....but still behind SFX-01 and a way to go before they're ready for Phase 2/3....and Reata Pharma, the US Bio also focussed on Nrf2 activation with a market cap of over $3.5 Billion.........EVG's got bags of transformational upside potential......Gla holders.....get ready for the new CEO and raft of positive news thereafter.........the slimey kingalf and his saddo mates aren't going to like it.....ho ho ho ;-)

DEFINE COVID-19

DEFINE is a clinical study which aims to test promising new therapies in small numbers of COVID-19 patients.

This clinical study will compare promising additional treatments against standard care (i.e. only treatments given routinely by your doctor/nurse) in patients who are experiencing different symptoms of COVID-19, either in the community or in a hospital environment. In order to assess how well the treatments are working, the study team will look at how safe and tolerable certain treatments are, and also measure small molecules in the blood and other samples called biomarkers. Biomarkers are molecules normally found in blood, other body fluids, or tissues and can be a sign of a normal or abnormal process, or of a condition or disease. In addition, knowing how certain biomarkers change (or not) with certain treatments will help us to understand how to tailor therapies for future COVID-19 patients.

The DEFINE clinical study is an Urgent Public Health (UPH) badged study which means this research will have an impact on public health within 12 months and that the science underpinning the proposed study is compelling.

You can learn more about the different aspects of the study by using the links below.

Visit the STOPCOVID webpages
Participant Information

The following documents contain information provided to participants in the DEFINE study.
DEFINE Participant Information Sheet (292.44 KB PDF)
DEFINE Participant Information Summary (147.91 KB PDF)

About the study
What is the purpose of the study?
Study timelines
Study design
Trial treatments
Taking part
Questions?

If you would like to ask about this study, please contact us.

Logos of DEFINE collaborators, including LifeArc, NHS Lothian and Accord.
Funders and collaborators

This adaptive trial platform is funded by LifeArc.

The study is sponsored by the University of Edinburgh and NHS Lothian through ACCORD.

The study has been given a favourable ethical opinion by the Scotland A ethics committee, the regulator and local Research and Development Departments.

https://www.ed.ac.uk/inflammation-research/clinical-trials/define-covid19

https://twitter.com/profjdchalmers?lang=en

ps Prof Chalmers and Prof Albena Dinkova-Kostova are the lead investigators for SFX-01's proposed Covid-19 patient trials.

https://discovery.dundee.ac.uk/en/persons/albena-dinkova-kostova

SULSA

@SULSAtweets

·

30m

Today meet Prof Albena Dinkova-Kostova

@UoDMedicine

, collaborating with

@ProfJDChalmers

to study whether the anti-inflammatory Nrf2 activator sulforaphane can improve recovery and decrease the need for mechanical ventilation in patients with severe COVID-19 #ScotlandRespondsC19

1

2

SULSA

@SULSAtweets

·

Aug 20

Today say hello to Dr Annya Bruce

@EdinburghUni

who is part of DEFINE COVID-19, a clinical trial now recruiting, comparing treatments against standard care to identify biomarkers that could help tailor therapies for future patients #ScotlandRespondsC19

Scottish Universities Life Science Alliance

SULSA is a strategic alliance between eleven
Scottish Universities that aims to advance
Scotland’s research and innovation in the
life sciences

James D Chalmers Retweeted

SULSA

@SULSAtweets

·

19m

Today meet Prof Albena Dinkova-Kostova

@UoDMedicine

, collaborating with

@ProfJDChalmers

to study whether the anti-inflammatory Nrf2 activator sulforaphane can improve recovery and decrease the need for mechanical ventilation in patients with severe COVID-19 #ScotlandRespondsC19

I'll be amazed if we don't hear about the new CEO by month end and/or an update on proceedings......and so every chance of plenty of upside and back to 15p plus in anticiaption....;-)

F U....:-)

i did a couple of posts back!!!

Given that the majority of sp action for Evg generally happens the the afternoon, there's speculation that this could be interest from the US......SFX-10 is under evaluation for Chronic Kidney Disease at the highly prestigous University of Rochester in New York, and the $ billion plus Reata Pharma are focussed on Nrf2 activators and there are several connections, with the University of Dundee providing independent research on Reata's drug pipeline.

One of the lead investigators of SFX-01's Covid-19 patient trials started out working for the laboratory of Paul Talalay (Johns Hopkins University), where they the revolutionary discovery and connection of sulforaphane's panacea qualites.....and the majority of her research work has been centred on NRF2 and Sulforaphane, and so plenty of reasons why those from across the pond could be interested.....Blackstone Life Sciences , who recently invested $350m in Reata, have a $4.5 billion war chest for investing in bio's and so every reason why EVG could be of interest, given their interest in Reata's Nrf2 developments.....Gla ;-)

https://discovery.dundee.ac.uk/en/persons/albena-dinkova-kostova

ps radar, it's obvious that you have kept a close eye here since first invested at 7p, hence your list on how many times i might post a topic or opinion.....there are continually new investors looking in for the first time who might not be aware of near term news expectations, and as another week goes by, it is only natural and normal for those invested to speculate....now what's your excuse....with no shares!!!???

So your purpose here is deter investors, becuase you haven'y provided one scrap of positive opinion since i first invested here at 7p.....one a troll always a troll........now what's your purpose here.....sad pathetic creature.

Gla Holders....News of the new CEO coming soon, one would have thought with so much in the pipeline they would want there man in by the start of September....;-)

S7VT.... The large prints have been going on for a few months and the size of many of the trades have been extroadianry large, especially back in May/June, and so there's obviously a transfer of stock in progress with someone accumualting under the radar....Spreadex's recent disclosure is only a small fraction of the share transfers that have been noted ( ps Nolupus..Spreadex are a spread betting company where punters can bet long and short, and don't very often disclose who's holding what, but obviously at the moment they have a number who are holding EVG and are betting long ).........News of the appointment of a new CEO must be imminent imho, and maybe disclosure and an explanation of the massive share transfers will be made there is specualtion that the share transfer/accumulation could be connected to a potential strategic investor and or commercial JV partnership, whereby they invest in EVG's future development and receive a a percentage of the company....and maybe even have their own man at the helm, which would certainly explain why were still awaiting news of the new CEO......anyways, whatever materialises.....shouldn't be too much longer now...., EVG's prospects look very exciting from this bargain low sp and incredibly modest market cap , with so much potential upside on multiple targets. Gl ;-)

Radar. what's your purprpose here....not one positive post from you on EVG's prospects, only derision on a stock you're obviously not invested.....you scoffed at the speculation that SFX-01 might be considered for Covid-19 patient trials, and then funding was confirmed you actually thoght that SFX-01 was a vaccine...ha ha ha ha ......this is the EVG share forum where investors have the right to speculate on their investment from the information at hand, you disappear when the sp rises and then make an appearance when the sp dips.....pathetic creature......Gla Holders......potential transformational stacking UP on several fronts!!! ;-)

Greed, Lust, Avarice.....;-)